Showing results (11-20 of 25) with videos related to
Sort By:
Pageof 3
Journal of the National Cancer Institute|June 16, 2005
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinibDaphne A Haas-Kogan, Michael D Prados, Tarik Tihan, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2005
Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patientsRobert L Yauch, Thomas Januario, David A Eberhard, et al.Nature Methods|August 21, 2007
Highly efficient somatic-mutation identification using Escherichia coli mismatch-repair detectionBrock A Peters, Zhengyan Kan, Dragan Sebisanovic, et al.Pigment Cell & Melanoma Research|March 18, 2014
Targeted next generation sequencing identifies clinically actionable mutations in patients with melanomaWilliam R Jeck, Joel Parker, Craig C Carson, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 20, 2007
Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancerRoy S Herbst, Angela M Davies, Ronald B Natale, et al.BMC Medicine|November 16, 2013
Criteria for the use of omics-based predictors in clinical trials: explanation and elaborationLisa M McShane, Margaret M Cavenagh, Tracy G Lively, et al.Nature|October 18, 2013
Criteria for the use of omics-based predictors in clinical trialsLisa M McShane, Margaret M Cavenagh, Tracy G Lively, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2005
Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancerRoy S Herbst, David H Johnson, Eric Mininberg, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2005
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinibDavid A Eberhard, Bruce E Johnson, Lukas C Amler, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2006
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation statusMichael S Gordon, Daniela Matei, Carol Aghajanian, et al.Pageof 3